The diagnostic value of CYFRA21-1, NSE, CEA, hCAP18, TPS in lung cancer

Abstract

Objective To investigate the diagnostic value of serum cytokeratin 19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), neuron specific enolase (NSE), human cationic antimicrobial peptide 18 (hCAP18), and tissue polypeptide specific antigen (TPS) in lung cancer. Methods 52 patients with lung cancer were selected as lung cancer group, 45 patients with benign lung disease as benign lung disease group, 40 healthy individuals as normal group. The levels and positive detection rates of serum CYFRA21-1, NSE, CEA, hCAP18, TPS in three groups were detected and compared. Evaluated the diagnostic efficacy of each and combination detection of tumor markers. Results The levels of serum CYFRA21-1, NSE, CEA, hCAP18, TPS in lung cancer group were significantly higher than those in benign lung disease group and normal group (P<0.05). The positive detection rates of serum CYFRA21-1, NSE, CEA, hCAP18, TPS, and combination test in lung cancer group were 61.54%, 51.92%, 55.77%, 67.31%, 75.00%, 98.08%, which were higher than 8.89%, 11.11%, 6.67%, 11.11%, 11.11%, 13.33% in benign lung disease group and 2.50%, 2.50%, 5.00%, 5.00%, 7.50%, 7.50% in normal group (P<0.05). The sensitivity and accuracy of combination detection of five tumor biomarkers were 96.15% and 92.70%, which were higher than those of single tumor biomarker detection (P<0.05). Conclusion The combination detection of serum CYFRA21-1, NSE, CEA, hCAP18, and TPS can reduce missed diagnosis and improve accuracy in the diagnosis of lung cancer. Key words: Lung cancer; Cytokeratin 19 fragment; Neuron specific enolase; Human cationic antimicrobial peptide 18; Carcinoembryonic antigen; Tissue polypeptide specific antigen